|
|
| | TFEB activator 2 Basic information |
| Product Name: | TFEB activator 2 | | Synonyms: | TFEB activator 2;1,3-Dioxolo[4,5-g]isoquinoline, 5-[2-(5-fluoro-1H-indol-3-yl)ethyl]-5,6,7,8-tetrahydro-6-[(tetrahydro-2H-pyran-4-yl)methyl]- | | CAS: | 3027414-04-3 | | MF: | C26H29FN2O3 | | MW: | 436.52 | | EINECS: | | | Product Categories: | | | Mol File: | 3027414-04-3.mol |  |
| | TFEB activator 2 Chemical Properties |
| Boiling point | 600.865±55.00 °C(Press: 760.00 Torr)(predicted) | | density | 1.267±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 16.440±0.30(predicted) | | form | Solid | | color | White to off-white |
| | TFEB activator 2 Usage And Synthesis |
| Uses | TFEB activator 2 (compound 37) exhibits TFEB activation and lysosome biogenesis capabilities. TFEB activator 2 has effect on TFEB nuclear translocation with 72% (10μM 3h) and 94 % (30 μM 3h). TFEB activator 2 plays an important role in Alzheimer’s disease (AD). TFEB activator 2 can pass blood brain barrier[1]. | | References | [1] Jianhui Zhou, et al. Discovery and Optimization of Tetrahydroisoquinoline Derivatives To Enhance Lysosome Biogenesis as Preclinical Candidates for the Treatment of Alzheimer’s Disease. J Med Chem. 2024 Jun 13;67(11):8836-8861. DOI:10.1021/acs.jmedchem.4c00159 |
| | TFEB activator 2 Preparation Products And Raw materials |
|